NASDAQ:HSGX Histogenics (HSGX) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free HSGX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.11▼$1.2550-Day Range$0.16▼$3.0752-Week Range$0.08▼$1.43Volume6.83 million shsAverage Volume9.06 million shsMarket Capitalization$111.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Histogenics alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Histogenics Stock (NASDAQ:HSGX)Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). HSGX Stock News HeadlinesApril 8, 2023 | thetimes.co.ukFeargal Sharkey: Desperate revival of failed policies doesn’t add upSeptember 21, 2022 | streetinsider.comAspect Biosystems Appoints Three New Board Members - StreetInsider.comApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.September 21, 2022 | businesswire.comAspect Biosystems Appoints Three New Board Members - Business WireAugust 24, 2022 | investing.comAre Ocugen Or Amarin Good Stocks To Buy? - Investing.comAugust 5, 2022 | stockhouse.com2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - StockhouseJune 23, 2022 | gurufocus.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.comMay 25, 2022 | uk.investing.comOcugen Diversifies Its Pipeline With New Cell Therapy Platform By Benzinga - Investing.com UKApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.May 25, 2022 | globenewswire.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GlobeNewswireMay 24, 2022 | streetinsider.comOcugen (OCGN) Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - StreetInsider.comApril 18, 2022 | streetinsider.comForm DEF 14A Aurinia Pharmaceuticals For: Apr 18 - StreetInsider.comMarch 8, 2022 | investorplace.comOcugen Is Two Strikes in With a Third in the Books - InvestorPlaceOctober 26, 2021 | news.yahoo.comCN.ORTH: New Blood on The Board - Yahoo FinanceSeptember 21, 2021 | prnewswire.comGlobal Cell Therapy Market Outlook, Patent & Clinical Trials Report 2021-2028: Clinical & Commercial Insight On 32 Cell Therapies Available & Insight on 1600+ Cell Therapies in Clinical Trials - PRNewswireSeptember 8, 2021 | streetinsider.comForm 8-K APPLIED GENETIC TECHNOLO For: Sep 08 - StreetInsider.comSee More Headlines Receive HSGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical Appliances & Supplies Sub-IndustryN/A Current SymbolNASDAQ:HSGX CUSIPN/A CIK1372299 Webwww.histogenics.com Phone781-547-7900FaxN/AEmployees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.96% Return on Assets18.40% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-118.00Miscellaneous Outstanding Shares94,599,000Free FloatN/AMarket Cap$111.63 million OptionableNot Optionable Beta3.10 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Adam D. Gridley (Age 47)Interim Pres, CEO Treasurer, Sec., Consultant & Director Mr. Jonathan I. Lieber (Age 49)Interim Chief Financial Officer Mr. Stephen R. Kennedy (Age 62)Consultant Key CompetitorsEnvoy MedicalNASDAQ:COCHInogenNASDAQ:INGNCollPlant BiotechnologiesNASDAQ:CLGNVicarious SurgicalNYSE:RBOTMilestone ScientificNYSE:MLSSView All Competitors HSGX Stock Analysis - Frequently Asked Questions How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) posted its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.10. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Biosciences (IDXG), Novavax (NVAX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Ocular Therapeutix (OCUL), Trevena (TRVN), OPKO Health (OPK) and Synergy Pharmaceuticals (SGYP). When did Histogenics IPO? Histogenics (HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. This page (NASDAQ:HSGX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.